Experience

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the approximately $128 million follow-on offering by Orchard Therapeutics…

Davis Polk advised the underwriters in connection with an initial public offering of 5,750,000 shares of common stock of IDEAYA Biosciences, Inc. at $10.00 per share (which includes the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the follow-on offering of 8,050,000 shares of common stock of…

Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering of common stock of Applied Therapeutics, Inc. Applied…

Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $19 billion in aggregate principal amount of senior notes by Bristol-Myers…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760,000 shares of common stock of Intercept Pharmaceuticals, Inc. …

Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM Biopharmaceuticals, Inc. at $16.00 per share, for gross proceeds…

Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares representing 9,019,608 ordinary shares of the company. The ADSs…

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics,…

Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of 6,543,500 shares of common stock of TransMedics Group, Inc.,…